Anti-Human PD-1 & CTLA-4 Reference Antibody (Danvilostomig, RUO) (HS870386)

Name: Anti-Human PD-1 & CTLA-4 Reference Antibody (Danvilostomig, RUO)
Brand: abinScience
SKU: HS870386
Price: 176 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HS870386
Description	Danvilostomig (HS870386) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG1-kappa_scFv
Cible	CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, PD-1, CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	Q15116 & P16410
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	2599198-80-6
Contexte	Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody. • Cancer immunotherapy using checkpoint blockade., PMID:29567705 • The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870 • Immune-related adverse events of checkpoint inhibitors., PMID:32382051 • Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845 • Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113 • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885 • Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160 • Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858 • Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360 • Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704
Note	For research use only. Not suitable for clinical or therapeutic use.